Volume 2, Issue 1 (5-2019)
2019, 2(1): 0-0 |
Back to browse issues page
Ethics code: IR.MEDILAM.REC.1397.136
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azami M. Epidemiology of celiac disease in irritable bowel syndrome patients in Iran: a systematic review and met analysis study. Journal title 2019; 2 (1)
URL: http://newresearch.medilam.ac.ir/article-1-431-en.html
URL: http://newresearch.medilam.ac.ir/article-1-431-en.html
Ilam University of Medical Sciences, Ilam, Iran
Abstract: (2814 Views)
Aim: The present study was conducted to evaluate the prevalence, clinical symptoms and pathological findings of celiac disease (CD) in IBS patients in Iran.
Background: Several studies show high prevalence of CD in IBS patients, but the results are contradictory
Methods: The present study was conducted based on PRISMA protocol. The search was done using national and international online databases including Scopus, PubMed, Science Direct, Cochrane Library, Embase, Web of Science, Google Scholar search engine and Iranian databases.
Results: The pooled prevalence of CD in 2367 Iranian IBS patients was estimated to be 6.13% (95%CI: 4.11-6.05). The CD female-to-male ratio was: OR = 1.69 (95%CI: 0.86-3.32, P = 0.127). The serological prevalence of Anti tTG-IgA (11 studies with 2901 IBS patients) and AGA-IgG CD (4 studies with 936 IBS patients) was estimated to be 5.35% (95%CI: 3.60-7.89) and 6.35% (95% CI: 2.05-18.03), respectively. The clinical symptoms of CD among IBS patients included predominant diarrhea (47.78% [95%CI: 22.46-74.43]), predominant constipation (17.34% [95%CI: 9.17-30.35]), and alternative diarrhea and constipation (27.84% [95%CI: 11.57-53.23]). According to pathological findings based on Marsh classification, the prevalence of CD at stages 1, 2 and 3 were 30.89% (95%CI: 13.25-56.68), 36.56% (95%CI: 21.74-54.45) and 52.82% (95% CI: 14.48-88.13), respectively.
Conclusion: CD prevalence in Iranian IBS patients is higher than global estimates. It seems that examination of all IBS patients in terms of CD is necessary
Background: Several studies show high prevalence of CD in IBS patients, but the results are contradictory
Methods: The present study was conducted based on PRISMA protocol. The search was done using national and international online databases including Scopus, PubMed, Science Direct, Cochrane Library, Embase, Web of Science, Google Scholar search engine and Iranian databases.
Results: The pooled prevalence of CD in 2367 Iranian IBS patients was estimated to be 6.13% (95%CI: 4.11-6.05). The CD female-to-male ratio was: OR = 1.69 (95%CI: 0.86-3.32, P = 0.127). The serological prevalence of Anti tTG-IgA (11 studies with 2901 IBS patients) and AGA-IgG CD (4 studies with 936 IBS patients) was estimated to be 5.35% (95%CI: 3.60-7.89) and 6.35% (95% CI: 2.05-18.03), respectively. The clinical symptoms of CD among IBS patients included predominant diarrhea (47.78% [95%CI: 22.46-74.43]), predominant constipation (17.34% [95%CI: 9.17-30.35]), and alternative diarrhea and constipation (27.84% [95%CI: 11.57-53.23]). According to pathological findings based on Marsh classification, the prevalence of CD at stages 1, 2 and 3 were 30.89% (95%CI: 13.25-56.68), 36.56% (95%CI: 21.74-54.45) and 52.82% (95% CI: 14.48-88.13), respectively.
Conclusion: CD prevalence in Iranian IBS patients is higher than global estimates. It seems that examination of all IBS patients in terms of CD is necessary
: Cross sectional |
Subject:
General
Received: 2018/06/19 | Accepted: 2019/01/20 | Published: 2019/05/31
Received: 2018/06/19 | Accepted: 2019/01/20 | Published: 2019/05/31
Send email to the proposal executer
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |